Log in

Relevant bibliographies by topics / AS1411

Contents

Journal articles
Dissertations / Theses
Book chapters
Conference papers
Reports

Academic literature on the topic 'AS1411'

Author: Grafiati

Published: 4 June 2021

Last updated: 3 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'AS1411.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "AS1411"

1

Stuart, R. K., K. Stockerl-Goldstein, M. Cooper, et al. "Randomized phase II trial of the nucleolin targeting aptamer AS1411 combined with high-dose cytarabine in relapsed/refractory acute myeloid leukemia (AML)." Journal of Clinical Oncology 27, no. 15_suppl (2009): 7019. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.7019.

Full text

Abstract:

7019 Background: Aptamers are small synthetic oligonucleotides that form stable nuclease-resistant 3D structures and bind target proteins with specificity and affinity similar to antibodies. These “chemical antibodies” represent a new class of therapeutics. The AS1411 aptamer binds nucleolin on the surface of cancer cells and induces apoptosis. AS1411 has synergistic effects in combination with cytarabine on AML cell lines in vitro and in vivo. A phase I trial of AS1411 monotherapy in 30 patients with advanced cancer showed objective responses without serious toxicities. Methods: This open-lab

APA, Harvard, Vancouver, ISO, and other styles

2

Miranda, André, Tiago Santos, Eric Largy, and Carla Cruz. "Locking up the AS1411 Aptamer with a Flanking Duplex: Towards an Improved Nucleolin-Targeting." Pharmaceuticals 14, no. 2 (2021): 121. http://dx.doi.org/10.3390/ph14020121.

Full text

Abstract:

We have designed AS1411-N6, a derivative of the nucleolin (NCL)-binding aptamer AS1411, by adding six nucleotides to the 5′-end that are complementary to nucleotides at the 3′-end forcing it into a stem-loop structure. We evaluated by several biophysical techniques if AS1411-N6 can adopt one or more conformations, one of which allows NCL binding. We found a decrease of polymorphism of G-quadruplex (G4)-forming sequences comparing to AS1411 and the G4 formation in presence of K+ promotes the duplex folding. We also studied the binding properties of ligands TMPyP4, PhenDC3, PDS, 360A, and BRACO-

APA, Harvard, Vancouver, ISO, and other styles

3

Chen, Weiwei, Vijayalakshmi Sridharan, Sridharan Soundararajan, et al. "Activity and Mechanism of Action of AS1411 in Acute Myeloid Leukemia Cells." Blood 110, no. 11 (2007): 1604. http://dx.doi.org/10.1182/blood.v110.11.1604.1604.

Full text

Abstract:

Abstract AS1411 is a 26 base unmodified DNA aptamer which is currently in a Phase II clinical trial for the treatment of acute myeloid leukemia (AML) and will shortly enter a Phase II trial in renal cell carcinoma (RCC). AS1411 has previously been shown to have cytostatic (a result of arrest in S phase of the cell cycle) and cytotoxic effects on tumor cells, but not normal cells. AS1411 binds to nucleolin, which is overexpressed in the cytoplasm and on the surface of tumor cells. Treatment of MV4-11 cells (an AML-derived cell line) with low micromolar concentrations of AS1411 results in cell g

APA, Harvard, Vancouver, ISO, and other styles

4

Shah, Kirti, Hakim Djeha, Christy Richie, Grainne McGeever, and Colin Green. "AS1411, a Novel DNA Aptamer as a Potential Treatment of Acute Myelogenous Leukaemia (AML)." Blood 108, no. 11 (2006): 1996. http://dx.doi.org/10.1182/blood.v108.11.1996.1996.

Full text

Abstract:

Abstract AS1411 (formerly AGRO100) is the first nucleic acid aptamer to enter oncology trials and is currently in a Phase I study in renal and lung patients. AS1411 is a 26mer unmodified phosphodiester-based guanosine rich oligonucleotide which, as a dimer, forms a serum-resistant quartet structure. It is postulated to exert anti-cancer activity by binding to cell surface nucleolin resulting in S-phase cell cycle arrest. We have previously shown that AS1411 inhibits growth of a wide range of solid tumours, including lung, renal, prostate and colorectal with EC50s of 2 to 8 μM. In this series o

APA, Harvard, Vancouver, ISO, and other styles

5

Ogloblina, Anna M., Nunzia Iaccarino, Domenica Capasso, et al. "Toward G-Quadruplex-Based Anticancer Agents: Biophysical and Biological Studies of Novel AS1411 Derivatives." International Journal of Molecular Sciences 21, no. 20 (2020): 7781. http://dx.doi.org/10.3390/ijms21207781.

Full text

Abstract:

Certain G-quadruplex forming guanine-rich oligonucleotides (GROs), including AS1411, are endowed with cancer-selective antiproliferative activity. They are known to bind to nucleolin protein, resulting in the inhibition of nucleolin-mediated phenomena. However, multiple nucleolin-independent biological effects of GROs have also been reported, allowing them to be considered promising candidates for multi-targeted cancer therapy. Herein, with the aim of optimizing AS1411 structural features to find GROs with improved anticancer properties, we have studied a small library of AS1411 derivatives di

APA, Harvard, Vancouver, ISO, and other styles

6

Stuart, Robert Kenneth, and Gary Acton. "Relapsed and Refractory Acute Myeloid Leukemia (AML) Treated with AS1411 and Cytarabine: A Randomized Phase II Trial." Blood 112, no. 11 (2008): 1935. http://dx.doi.org/10.1182/blood.v112.11.1935.1935.

Full text

Abstract:

Abstract Background: AS1411 is an aptamer that binds to nucleolin, which is upregulated and overexpressed in the cytoplasm and on the cell surface of cancer cells. Combination of AS1411 with cytarabine produces synergistic effects on AML cell lines and in vivo models. A phase I trial of AS1411 monotherapy in 30 patients with various advanced cancers revealed no dose-limiting toxicities and showed evidence of activity, including 2 responses among 12 patients with metastatic renal cancer. This phase II study evaluates the addition of AS1411 to high-dose cytarabine in relapsed and refractory AML.

APA, Harvard, Vancouver, ISO, and other styles

7

Lee, Kyue Yim, Hyungu Kang, Sung Ho Ryu, Dong Soo Lee, Jung Hwan Lee, and Soonhag Kim. "Bioimaging of Nucleolin Aptamer-Containing 5-(N-benzylcarboxyamide)-2′-deoxyuridine More Capable of Specific Binding to Targets in Cancer Cells." Journal of Biomedicine and Biotechnology 2010 (2010): 1–9. http://dx.doi.org/10.1155/2010/168306.

Full text

Abstract:

Chemically modified nucleotides have been developed and applied into SELEX procedure to find a novel type of aptamers to fit with targets of interest. In this study, we directly performed chemical modification of 5-(N-benzylcarboxyamide)-2′-deoxyuridine (called 5-BzdU) in the AS1411 aptamer, which binds to the nucleolin protein expressed in cancer cells. Forty-seven compounds of AS1411-containing Cy3-labeled 5-BzdU (called Cy3-(5-BzdU)-modified-AS1411) were synthesized by randomly substituting thymidines one to twelve in AS1411 with Cy3-labeled 5-BzdU. Both statistically quantified fluorescenc

APA, Harvard, Vancouver, ISO, and other styles

8

Lopes-Nunes, Jessica, Ana S. Agonia, Tiago Rosado, et al. "Aptamer-Functionalized Gold Nanoparticles for Drug Delivery to Gynecological Carcinoma Cells." Cancers 13, no. 16 (2021): 4038. http://dx.doi.org/10.3390/cancers13164038.

Full text

Abstract:

Cervical cancer is one of the most common cancers and is one of the major cause of deaths in women, especially in underdeveloped countries. The patients are usually treated with surgery, radiotherapy, and chemotherapy. However, these treatments can cause several side effects and may lead to infertility. Another concerning gynecologic cancer is endometrial cancer, in which a high number of patients present a poor prognosis with low survival rates. AS1411, a DNA aptamer, increases anticancer therapeutic selectivity, and through its conjugation with gold nanoparticles (AS1411-AuNPs) it is possibl

APA, Harvard, Vancouver, ISO, and other styles

9

Ga, Lu, Jun Ai, and Yong Wang. "AS1411-Templated Fluorescent Cu Nanomaterial’s Synthesis and Its Application to Detecting Melamine." Journal of Chemistry 2020 (May 20, 2020): 1–6. http://dx.doi.org/10.1155/2020/4067578.

Full text

Abstract:

Herein, we report a novel approach to AS1411-templated formation of fluorescent copper nanomaterials and their application to melamine detection. Fluorescent copper nanomaterials were formed at room temperature by using AS1411 as a template and ascorbic acid as reductant. However, the fluorescence intensity decreased obviously in the presence of melamine. Under the optimized conditions, the quenching fluorescence intensities of copper nanomaterials showed a good linear relationship with the concentration of melamine in the range of 50 μmol/L–120 μmol/L, and the correlation coefficient was 0.98

APA, Harvard, Vancouver, ISO, and other styles

10

Hu, Jianda, Yanxin Chen, Zhengjun Wu, et al. "Targeting Nucleolin for Reversal of Chemotherapy Resistance in Acute Lymphoblastic Leukemia." Blood 134, Supplement_1 (2019): 5058. http://dx.doi.org/10.1182/blood-2019-127073.

Full text

Abstract:

Chemotherapy resistance is considered to be the principal cause of ineffective treatment in acute lymphoblastic leukemia (ALL). Nucleolin (NCL) is high expression andplays oncogenic roles in most cancers. However, less research on the role of NCL in hematologic malignancies was noted. Our previous studies have showed that overexpression of NCL was associated with worse prognosis in the patients with acute leukemia and NCL expressionwashigher in resistant HL-60/ADR than in sensitive HL-60 cells. The potential mechanisms of NCL in chemotherapy resistance have yet to be revealed. Here we presente

APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "AS1411"

1

Kabirian, Dehkordi Samaneh. "Biological Activities of Nucleolin Aptamer AS1411 Grafted to Gold Nanospheres : From Synthesis to Mechanistic Studies." Thesis, Lyon, 2019. http://www.theses.fr/2019LYSE1216.

Full text

Abstract:

Un oligonucléotide riche en G, AS1411, interagi avec la nucléoline et inhibe la prolifération des cellules cancéreuses et la croissance tumorale. Cette action antiproliférative est augmentée lorsqu’AS1411 est conjugué à différents types de nanoparticules. Cependant, les mécanismes moléculaires impliqués demeurent inconnusDans ce travail, nous montrons dans des cellules HeLa que l'optimisation des nanopshères d'or conjuguées à l'AS1411 (GNS-AS1411) inhibe l'expression de la nucléoline aux niveaux des ARN et des protéines. Une altération de la structure nucléolaire avec une diminution de l’accum

APA, Harvard, Vancouver, ISO, and other styles

2

Chiu, Shih-Jen, and 邱詩任. "One-step Synthesis of Irregular Shaped Gold Nanoparticles Modified with AS1411 for the Inhibition of Cancer Cell Growth." Thesis, 2017. http://ndltd.ncl.edu.tw/handle/02490312591110911951.

Full text

Abstract:

碩士<br>國立臺灣海洋大學<br>生命科學暨生物科技學系<br>105<br>AS1411 is a guanine-rich (G-rich) oligodeoxyribonucleotide aptamer, which can form a stable G-quadruplex structure. Studies show that AS1411 can specifically bind to nucleolin (NCL), a multifunctional nucleolar protein located in cell. NCL is overexpressed on cell membrane in most cancer cells. Hence, AS1411-conjugated nanoparticles can be internalized in to the cells via receptor-mediated endocytosis after they specifically interact with nucleolin on the cell membrane, that enables cancer cell labeling and inhibition of cell growth. In this study, we de

APA, Harvard, Vancouver, ISO, and other styles

3

Antunes, Francisca Ferreira. "Nanosistema de entrega de fármacos para o tratamento de infeções por HPV." Master's thesis, 2018. http://hdl.handle.net/10400.6/9994.

Full text

Abstract:

O AS1411 é uma sequência de oligonucleótidos rica em guaninas e altamente polimórfica, apresentando uma ampla variedade de estruturas de G-quadruplex (G4). Este aptamero é seletivo para a nucleolina (NCL), uma proteína sobre-expressa em muitas células cancerosas e que se apresenta como um potencial alvo terapêutico. Devido à ligação à NCL, o aptamero G4 AS1411 pode ser internalizado por estas células. Embora o G4 AS1411 apresente um perfil de segurança e capacidade de induzir respostas em alguns pacientes, é importante melhorar a sua farmacologia e potência, de forma a proporcionar uma melhor

APA, Harvard, Vancouver, ISO, and other styles

4

Lopes, Ana Catarina Gonçalves. "Nanosistema de entrega de fármacos para tratamento de infeções por HPV." Master's thesis, 2018. http://hdl.handle.net/10400.6/9832.

Full text

Abstract:

Sequências de oligonucleótidos de DNA e RNA ricas em guaninas podem associar-se inter ou intramolecularmente para formar estruturas de quatro cadeias que se designam G-quadruplex (G4). Vários oligodesoxinucleótidos de G4 têm sido alvo de estudo como potenciais agentes diagnóstico e terapêuticos funcionando como aptameros, pois têm interação específica com proteínas alvo que podem encontrar-se à superfície das células. Entre estes alvos está a nucleolina (NCL), proteína multifuncional sobrexpressa à superfície das células cancerosas, sendo por isso um alvo para o desenvolvimento estratégias par

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "AS1411"

1

Reyes-Reyes, Elsa M., and Paula J. Bates. "Characterizing Oligonucleotide Uptake in Cultured Cells: A Case Study Using AS1411 Aptamer." In Methods in Molecular Biology. Springer New York, 2019. http://dx.doi.org/10.1007/978-1-4939-9670-4_10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

"Pharmacotherapy for Substance Use Disorders." In Manual of Clinical Psychopharmacology. American Psychiatric Publishing, 2015. http://dx.doi.org/10.1176/appi.books.9781615370047.as11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Carpenter, Linda, and Alan Schatzberg. "Sertraline." In The American Psychiatric Association Publishing Textbook of Psychopharmacology. American Psychiatric Association Publishing, 2017. http://dx.doi.org/10.1176/appi.books.9781615371624.as11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Roseboom, Patrick, and Ned Kalin. "Citalopram and Escitalopram." In The American Psychiatric Association Publishing Textbook of Psychopharmacology. American Psychiatric Association Publishing, 2017. http://dx.doi.org/10.1176/appi.books.9781615371624.as14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Kraemer, Helena, and Alan Schatzberg. "Statistics, Placebo Response, and Clinical Trial Design in Psychopharmacology." In The American Psychiatric Publishing Textbook of Psychopharmacology. American Psychiatric Publishing, 2009. http://dx.doi.org/10.1176/appi.books.9781585623860.as11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Block, David, Kimberly Yonkers, and Linda Carpenter. "Sertraline." In The American Psychiatric Publishing Textbook of Psychopharmacology. American Psychiatric Publishing, 2009. http://dx.doi.org/10.1176/appi.books.9781585623860.as14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

"Pharmacotherapy for Substance Use Disorders." In Schatzberg’s Manual of Psychopharmacology. American Psychiatric Association Publishing, 2019. http://dx.doi.org/10.1176/appi.books.9781615372300.as11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

"Pharmacotherapy for Substance Use Disorders." In Schatzberg’s Manual of Psychopharmacology. American Psychiatric Association Publishing, 2019. http://dx.doi.org/10.1176/appi.books.9781615372997.as11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "AS1411"

1

Shieh, M. J., Y. A. Shieh, and P. S. Lai. "AS1411 aptamer for targetable photosensitizer delivery." In 2009 International Conference on Biomedical and Pharmaceutical Engineering (ICBPE). IEEE, 2009. http://dx.doi.org/10.1109/icbpe.2009.5384070.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Trinh, Thu Le, Guizhi Zhu, Xilin Xiao, et al. "Abstract B97: AS1411-Doxorubicin adduct for targeted liver cancer therapy." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Oct 19-23, 2013; Boston, MA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.targ-13-b97.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Reyes-Reyes, Elsa M., Francesca R. Salipur, and Paula J. Bates. "Abstract 1046: AS1411 activity is regulated by epidermal growth factor receptor signaling pathway." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-1046.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Teng, Yun, David Jones, Fiona McLaughlin, and Paula J. Bates. "Abstract 3642: AS1411 causes a specific increase in levels of cell surface nucleolin in responsive cell lines." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-3642.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Senderovich, Shai, Alfred Ajami, Ben Doran, Fiona McLaughlin, and David Jones. "Abstract 3647: Gene expression analysis in AML cell line MV4-11 following treatment with the anti-cancer aptamer AS1411." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-3647.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Islam, Ashraful, David Jones, Fiona McLaughlin, and Paula J. Bates. "Abstract 4455: Differential response to AS1411 in a pair of VHL-positive and VHL-negative renal carcinoma cell lines." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-4455.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Green, Colin, Hakim Djeha, Michael Bestwick, Donna Dobinson, and Fiona McLaughlin. "Abstract 2614: Anti-tumor efficacy and pharmacokinetics of the novel aptamer AS1411 in a continuous infusion nude rat xenograft model." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-2614.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Reyes-Reyes, Elsa M., and Paula J. Bates. "Abstract 4450: A new paradigm for AS1411 activity: Uptake by macropinocytosis and induction of macropinocytosis by a nucleolin-dependent mechanism." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-4450.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Senderovich, Shai, David Jones, Alfred Ajami, and Fiona McLaughlin. "Abstract 3665: The novel DNA intercalator amonafide (AS1413), disrupts the cell cycle by mechanisms distinct from those of Topo II inhibitors daunorubicin and etoposide." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-3665.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Seijas, Julio A., M. Pilar Vázquez-Tato, Alberto Mena-Menéndez, and Xesús Feás. "Novel Microwave-assisted Synthesis of the Organotellurium Compound Ammonium Trichloro (dioxoethylene-O,O\') Tellurate (AS101)." In The 16th International Electronic Conference on Synthetic Organic Chemistry. MDPI, 2012. http://dx.doi.org/10.3390/ecsoc-16-01079.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "AS1411"

1

Abley, J., and W. Maton. AS112 Nameserver Operations. RFC Editor, 2011. http://dx.doi.org/10.17487/rfc6304.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Abley, J., and W. Sotomayor. AS112 Nameserver Operations. RFC Editor, 2015. http://dx.doi.org/10.17487/rfc7534.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Abley, J., B. Dickson, W. Kumari, and G. Michaelson. AS112 Redirection Using DNAME. RFC Editor, 2015. http://dx.doi.org/10.17487/rfc7535.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!